BPC-157 is explicitly named on the WADA Prohibited List (Section S0) since 2022
In yet another embodiment, the formulation or composition comprises a wetting agent
Disclaimer: This product description is for informational purposes only and does not constitute medical, scientific, or regulatory advice
Some people may experience temporary redness, swelling, or irritation at the injection site, while others might notice changes in appetite, water retention, joint aches, or mild fatigue
It is intended for use as a sterile solvent or diluent vehicle for medications approved for subcutaneous or intramuscular injection in laboratory research settings
Vitobit B12 Injection is administered by a healthcare professional